Brunner K W
Schweiz Med Wochenschr. 1978 Dec 9;108(49):1947-58.
The development of curative treatment for malignant lymphoma over the last few years is described. Hodgkin's disease and non-Hodgkin lymphomas are discussed separately. The current improved cure rates for Hodgkin's disease have become possible only with more exact determination of disease stage and a clinically relevant histological classification and definition of other risk factors. These prognostic criteria provide the basis for determining whether radiotherapy alone, chemotherapy alone, or a combination of radiotherapy and chemotherapy offers the best chance for cure. --For the much more heterogenous disease group of non-Hodgkin lymphomas, a similar line of development is in progress. Here better forms of chemotherapy have been of primary importance and have significantly improved the prospects of cure, especially for cases in stage III and IV with unfavorable histologies. Combination treatment with radio- and chemotherapy is still in the developmental stage for non-Hodgkin lymphomas. The place of large volume radiotherapy such as total body or total abdominal irradiation has still to be determined.
本文描述了过去几年中恶性淋巴瘤治疗方法的发展。霍奇金病和非霍奇金淋巴瘤将分别进行讨论。目前霍奇金病治愈率的提高，只有通过更准确地确定疾病分期、临床相关的组织学分类以及其他危险因素的定义才得以实现。这些预后标准为确定单独放疗、单独化疗或放疗与化疗联合使用是否提供最佳治愈机会提供了依据。——对于更为异质性的非霍奇金淋巴瘤疾病组，类似的发展路线正在进行中。在这里，更好的化疗形式至关重要，并显著改善了治愈前景，特别是对于Ⅲ期和Ⅳ期组织学不良的病例。放疗与化疗的联合治疗对于非霍奇金淋巴瘤仍处于发展阶段。全身或全腹照射等大剂量放疗的作用仍有待确定。
